Related Experiment Video
Updated: Jul 14, 2026

Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice
Published on: October 25, 2024
In vivo molecular imaging biomarkers: clinical pharmacology's new "PET"?
R Nutt1, L J Vento, M H T Ridinger
1Advanced Biomarker Technologies, LLC, Institute for Molecular Technologies, and Academy of Molecular Imaging, Knoxville, Tennessee, USA.
Abstract:
Medicine, including the pharmaceutical and biotechnology industries as well as many clinical practitioners, has recognized the importance of using molecular imaging biomarkers, including those labeled in such a way as to be imaged by positron emission tomography (PET), as tools for predicting outcomes in drug development and creating opportunities for "personalized" medicine, for diagnosing early-stage disease, and for the follow-up of the effectiveness of treatment.(1) However, only one important and widely used PET biomarker is currently approved by the Food and Drug Administration (FDA). If the technology is so important, we can ask why there is such a limitation to the availability of these biomarkers.
More Related Videos
Related Concept Videos
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET

